Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Tesevatinib |
Synonyms | |
Therapy Description |
XL647 is an inhibitor of multiple receptor tyrosine kinases, including ERBB2 (HER2), EGFR, VEGFR2 and VEGFR3, and EphB4, potentially resulting in decreased tumor growth and angiogenesis (PMID: 17575237). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Tesevatinib | KD019|XL647|EXEL 7647|KD 019 | EGFR Inhibitor (Pan) 47 EPHB4 Inhibitor 6 HER2 Inhibitor 26 VEGFR2 Inhibitor 35 VEGFR3 Inhibitor 5 | Tesevatinib (XL647) is an inhibitor of multiple receptor tyrosine kinases, including ERBB2 (HER2), EGFR, VEGFR2 and VEGFR3, and EphB4, potentially resulting in decreased tumor growth and angiogenesis (PMID: 17575237, PMID: 30030583). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ERBB2 L726F | Advanced Solid Tumor | sensitive | Tesevatinib | Preclinical - Cell culture | Actionable | In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) L726F in culture (PMID: 18413839). | 18413839 |
ERBB2 E812K | Advanced Solid Tumor | sensitive | Tesevatinib | Preclinical | Actionable | In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) E812K in culture (PMID: 18413839). | 18413839 |
ERBB2 E719G | Advanced Solid Tumor | sensitive | Tesevatinib | Preclinical | Actionable | In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) E719G in culture (PMID: 18413839). | 18413839 |
ERBB2 T798I | Advanced Solid Tumor | sensitive | Tesevatinib | Preclinical | Actionable | In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) T798I in culture (PMID: 18413839). | 18413839 |
ERBB2 E717K | Advanced Solid Tumor | sensitive | Tesevatinib | Preclinical | Actionable | In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) E717K in culture (PMID: 18413839). | 18413839 |
ERBB2 P780L | Advanced Solid Tumor | sensitive | Tesevatinib | Preclinical | Actionable | In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) P780L in culture (PMID: 18413839). | 18413839 |
ERBB2 L915M | Advanced Solid Tumor | sensitive | Tesevatinib | Preclinical - Cell culture | Actionable | In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) L915M in culture (PMID: 18413839). | 18413839 |
ERBB2 Y803N | Advanced Solid Tumor | sensitive | Tesevatinib | Preclinical | Actionable | In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) Y803N in culture (PMID: 18413839). | 18413839 |
ERBB2 L755S | Advanced Solid Tumor | sensitive | Tesevatinib | Preclinical | Actionable | In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) L755S in culture (PMID: 18413839). | 18413839 |
ERBB2 L785F | Advanced Solid Tumor | sensitive | Tesevatinib | Preclinical | Actionable | In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) L785F in culture (PMID: 18413839). | 18413839 |
ERBB2 T733I | Advanced Solid Tumor | sensitive | Tesevatinib | Preclinical | Actionable | In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) T733I in culture (PMID: 18413839). | 18413839 |
ERBB2 S783P | Advanced Solid Tumor | sensitive | Tesevatinib | Preclinical | Actionable | In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) S783P in culture (PMID: 18413839). | 18413839 |
ERBB2 D821N | Advanced Solid Tumor | sensitive | Tesevatinib | Preclinical | Actionable | In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) D821N in culture (PMID: 18413839). | 18413839 |
ERBB2 V839G | Advanced Solid Tumor | sensitive | Tesevatinib | Preclinical | Actionable | In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) V839G in culture (PMID: 18413839). | 18413839 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02844439 | Phase II | Tesevatinib | Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma | Completed | USA | 0 |
NCT02616393 | Phase II | Tesevatinib | Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases | Completed | USA | 0 |